Total Payments
$61,882
2024 Payments
$216.96
Companies
20
Transactions
105
Payment Breakdown by Category
Consulting$36,659 (59.2%)
Other$14,176 (22.9%)
Food & Beverage$4,454 (7.2%)
Research$3,323 (5.4%)
Travel$3,269 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,659 | 13 | 59.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,176 | 11 | 22.9% |
| Food and Beverage | $4,454 | 57 | 7.2% |
| Unspecified | $3,323 | 16 | 5.4% |
| Travel and Lodging | $3,269 | 8 | 5.3% |
Payments by Type
General
$58,559
89 transactions
Research
$3,323
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $17,736 | 15 | $0 (2023) |
| PFIZER INC. | $15,681 | 10 | $0 (2023) |
| Astellas Pharma US Inc | $7,075 | 6 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $6,966 | 9 | $0 (2023) |
| Seattle Genetics, Inc. | $6,381 | 5 | $0 (2019) |
| Seagen Inc. | $2,229 | 10 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $1,672 | 11 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $1,002 | 10 | $0 (2021) |
| Janssen Research & Development, LLC | $928.30 | 6 | $0 (2020) |
| Roche Products Limited | $807.47 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $216.96 | 2 | Aveo Pharmaceuticals, Inc. ($134.87) |
| 2023 | $9,925 | 21 | PFIZER INC. ($5,466) |
| 2022 | $15,700 | 29 | EMD Serono, Inc. ($7,206) |
| 2021 | $10,620 | 6 | EMD Serono, Inc. ($9,000) |
| 2020 | $6,526 | 10 | PFIZER INC. ($3,800) |
| 2019 | $12,258 | 25 | Seattle Genetics, Inc. ($6,381) |
| 2018 | $6,529 | 10 | Astellas Pharma US Inc ($5,515) |
| 2017 | $106.10 | 2 | Prometheus Laboratories Inc. ($93.53) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2024 | Aveo Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $134.87 | General |
| 03/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $82.09 | General |
| 11/27/2023 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,530.00 | General |
| 10/22/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $66.41 | General |
| 08/14/2023 | PFIZER INC. | BAVENCIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $133.65 | General |
| Category: HORMONE THERAPY | ||||||
| 07/31/2023 | PFIZER INC. | BAVENCIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $125.40 | General |
| Category: Oncology | ||||||
| 06/05/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $32.37 | General |
| 06/02/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $133.40 | General |
| 04/26/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $95.89 | General |
| Category: Oncology | ||||||
| 03/14/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $132.29 | General |
| Category: Oncology | ||||||
| 02/28/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.76 | General |
| 02/21/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $144.14 | General |
| Category: Oncology | ||||||
| 02/14/2023 | Seagen Inc. | — | — | In-kind items and services | $147.06 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/14/2023 | Seagen Inc. | — | — | In-kind items and services | $33.19 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $677.26 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $587.79 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $382.12 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $105.40 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $64.99 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 02/03/2023 | Seagen Inc. | — | — | In-kind items and services | $64.99 | Research |
| Study: A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | ||||||
| 12/31/2022 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,012.92 | General |
| 12/31/2022 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $715.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | Seagen Inc. | $2,063 | 8 |
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | Aveo Pharmaceuticals, Inc. | $1,260 | 8 |
About Dr. Helen Moon, M.D
Dr. Helen Moon, M.D is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1255480075.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helen Moon, M.D has received a total of $61,882 in payments from pharmaceutical and medical device companies, with $216.96 received in 2024. These payments were reported across 105 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($36,659).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Pasadena, CA
- Active Since 01/10/2007
- Last Updated 11/01/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255480075
Products in Payments
- Bavencio (Drug) $11,500
- BAVENCIO (Drug) $11,400
- XTANDI (Drug) $11,185
- Nubeqa (Drug) $5,253
- Xofigo (Drug) $1,713
- FOTIVDA (Drug) $1,537
- PROVENGE (Drug) $1,002
- TECENTRIQ (Biological) $868.92
- ORGOVYX (Drug) $133.65
- TAGRISSO (Drug) $130.10
- PLUVICTO (Drug) $114.99
- Yescarta (Drug) $18.93
- TYSABRI (Biological) $12.57
- Clinical Trials Matching (Device) $12.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Pasadena
Dr. Yuan Yuan, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $523,801
Internal Medicine $523,801
Christopher Dagher, M.d, M.D
Internal Medicine — Payments: $103,615
Internal Medicine $103,615
Peter Haddad, M.d, M.D
Internal Medicine — Payments: $87,600
Internal Medicine $87,600
Dr. Andrew Williams, M.d, M.D
Internal Medicine — Payments: $85,273
Internal Medicine $85,273
Joseph Dellinger, Md, MD
Internal Medicine — Payments: $77,175
Internal Medicine $77,175
John Debeixedon, M D, M D
Internal Medicine — Payments: $50,465
Internal Medicine $50,465